Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Asthma is a complex disease with multiple phenotypes that may differ in disease pathobiology and treatment response. IL33 single nucleotide polymorphisms (SNPs) have been reproducibly associated with asthma. IL33 levels are elevated in sputum and bronchial biopsies of patients with asthma. The functional consequences of IL33 asthma SNPs remain unknown.
Objective: This study sought to determine whether IL33 SNPs associate with asthma-related phenotypes and with IL33 expression in lung or bronchial epithelium. This study investigated the effect of increased IL33 expression on human bronchial epithelial cell (HBEC) function.
Methods: Association between IL33 SNPs (Chr9: 5,815,786-6,657,983) and asthma phenotypes (Lifelines/DAG [Dutch Asthma GWAS]/GASP [Genetics of Asthma Severity & Phenotypes] cohorts) and between SNPs and expression (lung tissue, bronchial brushes, HBECs) was done using regression modeling. Lentiviral overexpression was used to study IL33 effects on HBECs.
Results: We found that 161 SNPs spanning the IL33 region associated with 1 or more asthma phenotypes after correction for multiple testing. We report a main independent signal tagged by rs992969 associating with blood eosinophil levels, asthma, and eosinophilic asthma. A second, independent signal tagged by rs4008366 presented modest association with eosinophilic asthma. Neither signal associated with FEV, FEV/forced vital capacity, atopy, and age of asthma onset. The 2 IL33 signals are expression quantitative loci in bronchial brushes and cultured HBECs, but not in lung tissue. IL33 overexpression in vitro resulted in reduced viability and reactive oxygen species-capturing of HBECs, without influencing epithelial cell count, metabolic activity, or barrier function.
Conclusions: We identify IL33 as an epithelial susceptibility gene for eosinophilia and asthma, provide mechanistic insight, and implicate targeting of the IL33 pathway specifically in eosinophilic asthma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2020.04.051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of biventricular function in asthmatic children with different severity by new echocardiographic modalities.
BMC Pediatr
September 2025
Department of Pediatrics, Faculty of Medicine, Tanta University, Tanta, Egypt.
Background: This study aimed to evaluate the impact of asthma severity on biventricular cardiac functions using tissue Doppler imaging (TDI), two-dimensional speckle tracking echocardiography (2D-STE), and three-dimensional speckle tracking echocardiography (3D-STE).
Methods: Sixty-three children with asthma, aged between 5 and 16 years, were enrolled in the study along with 63 matched controls. All participants underwent cardiac assessments, including TDI, 2D-STE, 3D-STE, conventional echocardiography, and pulmonary function testing with spirometry.
Clinical efficacy of mepolizumab and dupilumab for eosinophilic otitis media: Analysis of patient clinical characteristic.
Allergol Int
September 2025
Department of Otolaryngology/Deafness and Middle Ear Surgicenter, Tokyo Kita Medical Center, Tokyo, Japan; Department of Otolaryngology - Head and Neck Surgery, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Background: Eosinophilic otitis media (EOM) is characterized by eosinophilic infiltration of the middle ear; it is frequently associated with bronchial asthma and chronic rhinosinusitis with nasal polyposis. Although biologics have been used to treat EOM, their efficacy based on clinical characteristics remains unclear. In this study, we evaluated the effectiveness of biologics and analyzed the clinical factors that influenced outcomes.
View Article and Find Full Text PDF[Progress on biologic therapies for severe asthma].
Zhonghua Jie He He Hu Xi Za Zhi
September 2025
Department of Allergy and Clinical Immunology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, G
Biologics play a critical role in the treatment of severe bronchial asthma. Both () and in our country recommend currently approved biologics as add-on therapies for patients whose symptoms remain uncontrolled despite high dose maintenance ICS-LABA treatments. The approved biologics include Omalizumab, Mepolizumab, Benralizumab, Reslizumab, Dupilumab, and Tezepelumab.
View Article and Find Full Text PDF[A case report of delayed drug hypersensitivity reaction caused by inhalation and nasal spray of budesonide].
Zhonghua Jie He He Hu Xi Za Zhi
September 2025
Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment on Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Inhaled and intranasal corticosteroids are widely used in the management of allergic respiratory diseases. Delayed drug hypersensitivity reactions to budesonide are a rare adverse drug reaction characterized by non-immunoglobulin E (IgE)-mediated clinical manifestations, including localized or systemic contact dermatitis, mucosal edema, and paradoxical worsening of pre-existing symptoms. However, such reactions are often underdiagnosed due to atypical presentations.
View Article and Find Full Text PDFArtificial Intelligence in allergy and immunology: recent developments, implementation challenges, and the road towards clinical impact.
J Allergy Clin Immunol
September 2025
University of Groningen, University Medical Center Groningen, Beatrix Children's Hospital, Department of Pediatric Pulmonology and Pediatric Allergology, Groningen, the Netherlands; University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC)
Artificial intelligence (AI) is increasingly recognized for its capacity to transform medicine. While publications applying AI in allergy and immunology have increased, clinical implementation substantially lags behind other specialties. By mid-2024, over 1,000 FDA-approved AI-enabled medical devices existed, but none specifically addressed allergy and immunology.
View Article and Find Full Text PDF